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Abstract
Background: The diagnosis of tuberculous meningitis (TBM) can be extremely difficult in the absence of culture
confirmation. Cerebrospinal fluid (CSF) adenosine deaminase (ADA) can potentially assist in this regard, although its
current value remains unclear. The literature on the usefulness of CSF ADA in TBM diagnosis is inconsistent, especially
from an analytical point of view.
Methods: A retrospective analysis of clinical and laboratory data relating to all CSF ADA requests during 2009 and 2010
in a South African quaternary healthcare setting was performed. A CSF ADA cut-off for TBM diagnosis was calculated
using receiver operating characteristic curve analysis. The performance of CSF ADA in different infective and non-infective
categories was assessed.
Results: In total, 3548 CSF ADA requests were considered over the 2-year period. Of these, 1490 were for patients for
whom both a CSF ADA and a mycobacterial culture were requested. The optimal cut-off was calculated at 2.0
U/L (AUC = 0.86; 95% CI = 0.82 – 0.89; p-value < 0.01; sensitivity of 85.9% (95% CI of 77.0 – 92.3) and specificity
of 77.7% (95% CI of 75.4 – 79.8%); positive likelihood ratio = 3.85 and negative likelihood ratio = 0.18). At this
cut-off 13 TBM cases were missed.
Conclusion: An optimal cut-off for routine use could not be established as too many TBM cases were missed. Specimen
integrity, lack of ADA assay standardisation and overlap in performance of the assay in different diagnostic categories
affect interpretation.
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Background
The diagnosis of tuberculous meningitis (TBM) in general
can be extremely difficult in the absence of culture con-
firmation. A non-definitive test such as cerebrospinal fluid
(CSF) adenosine deaminase (ADA) could potentially assist
in the regard, although its current value for the diagnosis
of TBM remains unclear.
South Africa is a low to middle income country with a
heavy burden of infectious diseases, particularly Human
Immunodeficiency virus (HIV) and tuberculosis. As the
diagnosis of TBM based on culture confirmation can take
weeks, clinicians rely heavily on CSF ADA as a rule-in test,
because of its fast turn-around time. However, as indicated
in Table 1, the sensitivity and specificity of CSF ADA uti-
lised in the diagnostic work-up of suspected TBM patients
cited in the literature vary considerably. One of the rea-
sons for this is the different cut-offs used. Mishra and col-
leagues reported a cut-off of 5 U/L with a sensitivity of
89% and specificity of 92% [1], whilst others have reported
a sensitivity of 66.6% and specificity of 90% using a cut-off
of 10 U/L [2] and a sensitivity of 100% and specificity of
99% using a cut-off of 20 U/L [3]. Furthermore, additional
confounding factors include, among others: differences in
the number of participants/specimens [4, 5], ages and
HIV-status(where stated) of participants [1, 3, 6–8] and
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variable definitions of TBM [1, 3, 9] and selection of
control groups [4, 6, 8]. Finally, various methods have been
used to measure CSF ADA such as those based on the
Giusti method [8, 10] or on non-Giusti methods [6, 11].
Many of the methods used are developed in-house [6, 12]
(see Table 1).
In view of the limitations described above, the objective
of this study was to determine an appropriate CSF ADA
cut-off level in a quaternary healthcare setting in South
Africa to assist in the diagnosis of TBM.
Methods
A retrospective study was conducted over a period of two
years (2009 and 2010) in which 3495 medical records were
reviewed. As some patients had more than one admission
the final number of records eligible for analysis was 3548
(see Fig. 1).
All adult and paediatric, male and female, as well as
HIV-positive and HIV-negative patients for whom a CSF
ADA was requested were included in this study. If a
patient had more than one specimen taken during a par-
ticular admission period, only the CSF ADA result from
the first specimen was considered. If more than one ad-
mission occurred during the study period, each admission
was considered as a separate event. All data previously
captured on the laboratory information system up to and
including the admission data from which the CSF ADA
test request originates were considered. Any subsequent
admissions and associated data where CSF ADA tests
were not requested, as well as results emanating from
other hospitals were excluded (see Fig. 1).
The cut-off age of 12 years was arbitrarily applied to
separate adult and paediatric patients thus including ad-
olescents in the adult patient category.
For the purpose of this study patients were considered
HIV-positive based on one of the following criteria: (1)
presence of a positive rapid test as well as a positive
enzyme-linked immunosorbent assay (ELISA), (2) pres-
ence of a positive initial and confirmatory ELISA, and
(3) presence of a positive polymerase chain reaction
(PCR) for HIV [13]. In addition (1) the presence of an
elevated HIV viral load, and (2) positivity for HIV as
stated in the patient file (where tests were done at a dif-
ferent laboratory) were used to assign HIV positivity. In
patients aged 18 months or younger, only the HIV PCR
result was considered to assign positivity to a patient in
this age group [13].
A CD4 absolute cell count of 350 x 106/L was used to
further classify patients according to the 2010 World
Health Organisation (WHO) guidelines regarding treat-
ment for HIV [14].
Subjects were categorised as ‘Confirmed TBM’ and vari-
ous infective non-tuberculous pathologies (confirmed
infective categories) according to definitive evidence (in-
cluding culture, molecular, and/or serological evidence).
For a specific breakdown of the cases considered for the
‘Confirmed TBM’ category, please see Table 2. In addition
suspected diagnoses of infective origin were captured sep-
arately (suspected infective categories) according to the evi-
dence as documented by clinicians in patient files. In
cases when CSF ADA was requested as part of a diagnos-
tic work-up, but a non-infectious diagnosis was ultimately
made by the clinician, a review of clinical, radiological and
histological evidence was performed to exclude the possi-
bility of TBM. The ‘Other’ category includes pathologies
not involving CSF or intracranial anatomy. The ‘No diag-
nosis made’ category includes patients where no clinical,
radiological or laboratory evidence was found to assign
patients to any of the other categories. CSF ADA perform-
ance was assessed in all these categories (see Fig. 2).
The Diazyme ADA assay (Diazyme, United States of
America) for the measurement of total ADA was used
Table 1 Factors confounding the interpretation of literature on CSF ADA
Factors Variables
CSF ADA cut-offs Study from India [1] 5 U/L Sensitivity: 89% Specificity: 92%
Study from India [2] 10 U/L Sensitivity: 66.6% Specificity: 90%
Study from Finland [3] 20 U/L Sensitivity: 100% Specificity: 99%
ADA assay types Giusti method [8, 10] Non-Giusti method [6, 11] In-house method [6, 12]
Total number of participants/specimens Range: 26 – 417 [4, 5]
Age of participants Adults only [3] Children only [1] Pooled data for adults and children [6]
Definition of TBM groups Clinical as well culture evidence was used to group participants [1]
Culture-positive cases sometimes was < 10 cases [3, 9]
Definition of control groups One infective category: bacterial meningitis only [4]
More than one infective category: viral/aseptic meningitis, bacterial meningitis, fungal meningitis [8]
Infective and non-infective categories: bacterial meningitis, viral meningitis, hydrocephalus, epilepsy,
malignancy, subarachnoid haemorrhage, senile dementia, normal CSF [6]
HIV status HIV status is not always specified in the literature [7, 8]
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and performed on a Pentra analyser (Horiba Medical
Diagnostics, Japan) with colorimetric detection. The
clinical decision limit for TBM used at this healthcare
facility was 6 U/L as determined in a South African
study by Blake and Berman [6].
The median, interquartile range (IQR), the 95% distri-
bution of values and outliers for the CSF ADA results
for each of the categories defined for this study were
determined.
All CSF ADA test results for the demographic categories
were compared using the Mann–Whitney test for non-
parametric data [15]. Similarly CSF ADA results for the
‘Confirmed TBM’ category were compared to all CSF
ADA results for patients where culture for Mycobacterium
tuberculosis complex (TB) on CSF was either not re-
quested or negative, i.e. on the total population for this
study (n = 3548). Using the Mann–Whitney test, CSF
ADA results in the confirmed infective categories were
compared between ‘Confirmed viral meningitis/encephal-
itis’, ‘Confirmed ventriculitis’, ‘Confirmed bacterial meningi-
tis’ and ‘Confirmed TBM’ groups.
Receiver operating characteristic (ROC) curves and
the Youden index were generated to establish the opti-
mal cut-off point for ADA interpretation in patients for
whom a CSF specimen was submitted for both mycobac-
terial culture and ADA determination [16]. Using the
optimal cut-off point, sensitivity and specificity, as well
as positive and negative likelihood ratios were deter-
mined. A p-value of < 0.05 was considered statistically
significant.
The dataset (n = 1490) was arbitrarily split into a train-
ing and validation cohort after random assignment of
values to each of the CSF ADA results to assess for over-
fitting of the model. The ROC curve and Youden index
Table 2 Breakdown of cases considered for the ‘Confirmed TBM’ category (n = 92)
Patients Reason for assigning patients to the ‘Confirmed TBM’ category
88 patients 83 patients Patients admitted to hospital for the first time and were culture positive
5 patients Known patients, where culture positivity was determined in a previous admission
during the 2009 – 2010 period; the patient still fell within the 9–12 months treatment
period; the CSF specimen in the current admission was negative on culture
4 patients Patients were positive for acid-fast bacilli on microscopy onlya
a These four patients where included due to HIV status (including CD4 count < 350 × 106/L) and/or had suspicious radiological findings
Fig. 1 Flow of participants throughout the study. Key to Fig. 1: ? – Suspected infective categories, dx - diagnosis. Confirmed infective categories:
refers to all those infective categories where the ‘?’ is omitted. For further breakdown of the ‘Confirmed TBM category’ please see Table 2
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was generated for the training set. The CSF ADA cut-off
point determined was applied to the validation set. The
same diagnostic accuracy parameters were determined
for the validation cohort as above.
For each of the demographic categories from which a
CSF sample was submitted for mycobacterial culture
and ADA determination, ROC curve analysis was uti-
lised to determine differences in these groups’ cut-off
point for ADA. The area under the curve (AUC) was
used to compare the individual ROC curves [15].
CSF sample integrity as determined by its appearance
(clear, turbid, bloodstained and xanthochromic) was
used to re-categorise CSF ADA results and these cat-
egories were compared by establishing the minimum,
median, and maximum values as well as the interquartile
ranges (IQRs).
A uniform case definition for diagnosis of TBM as deter-
mined by Marais and colleagues was used to re-categorise
patients and CSF ADA results were assessed in each of the
categories [17]. The CSF ADA result is not included in this
definition.
Statistical analyses were performed on Analyse-it
(Analyse-it Software, Ltd., United Kingdom).
Results
The majority of the patients in this study were adults
(n = 3170, 89.3%), of which 2009 individuals (56.6%)
were between the ages of 20 and 40 years. Male and female
patients were roughly equal in number (n = 1721, 48.5%
and n = 1824, 51.4% respectively). Most patients were
HIV-positive (n = 1970, 55.5%). Of the total popula-
tion, CD4 cell counts for 1456 (41.0%) patients mea-
sured ≤ 350 x 106/L. Table 3 summarises the demographic
characteristics, HIV status and the CD4 cell count as de-
termined by the medical records reviewed (n = 3548).
The performance of CSF ADA measurement in each
of the infective and non-infective categories is shown in
Fig. 2. Figure 2 shows the outlier values in terms of IQR
Fig. 2 CSF ADA values for each of the categories. Key to Fig. 2: CI - confidence interval; IQR - interquartile range; ? - Suspected infective categories, dx -
diagnosis. Confirmed infective categories: refers to all those infective categories where the ‘?’ is omitted
Table 3 Demographic characteristics, HIV status and the CD4 cell
count as determined by the medical records reviewed (n = 3548)
Age Adult patients: n = 3170 (89.3%)
Paediatric patients: n = 365 (10.3%)
No information regarding age available:
n = 13 (0.4%)
Sex Male patients: n = 1721 (48.5%)
Female patients: n = 1824 (51.4%)
No information regarding sex available:
n = 3 (0.1%)
HIV status HIV-positive patients: n = 1970 (55.5%)
HIV-negative patients: n = 693 (19.5%)
No information regarding HIV status available:
n = 885 (25%)
CD4 cell count Patients with CD4 cell count > 350 × 106/L:
n = 235 (6.6%)
Patients with CD4 cell count≤ 350 × 106/L:
n = 1456 (41.0%)
No information regarding CD4 cell count available:
n = 1857 (52.3%)
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as well as the 95% distribution of the values in each of
the categories. Notably the total number of CSF ADA
results (n = 3548) follow a non-parametric distribution.
For the majority of results (n = 3415) CSF ADA values
were less than 10 U/L. The CSF ADA results in Fig. 2 in-
dicate a considerable overlap, not only in the outliers for
each category, but also in each category’s 95% distribu-
tion of values. Of note the ‘Confirmed ventriculitis’ cat-
egory had the widest 95% distribution of values.
In all comparisons of CSF ADA results were higher in
adult than paediatric patients (p < 0.02), higher in male
than female patients (p < 0.01), higher in HIV-positive
than HIV-negative patients (p < 0.01) and higher in pa-
tients with CD4 cell counts ≤ 350 × 106/L as opposed to
patients with CD4 cell counts > 350 × 106/L (p < 0.01).
In Table 4 ‘Confirmed TBM’ CSF ADA results (n = 92)
are compared to all CSF ADA results for patients where
TB culture on CSF was either absent or negative (n =
3456). Similar statistically significant results (p < 0.01)
were obtained from the sub-set analysis of medical re-
cords (n = 1490) where both culture and ADA was re-
quested on a CSF specimen.
Individually all CSF ADA results in the ‘Confirmed
cryptococcal meningitis’, ‘Confirmed bacterial meningitis’,
‘Confirmed viral meningitis/encephalitis’ and ‘Confirmed
ventriculitis’ categories were compared with the ‘Con-
firmed TBM’ category (see Table 5). Statistically signifi-
cant differences were noted in the comparisons between
the ‘Confirmed TBM’ and ‘Confirmed cryptococcal men-
ingitis’ and ‘Confirmed viral meningitis/encephalitis’ cat-
egories (p < 0.01). This however was not the case in the
comparison between the ‘Confirmed bacterial meningi-
tis’ and ‘Confirmed TBM’ categories (p = 0.06) and the
‘Confirmed ventriculitis’ and ‘Confirmed TBM’ categor-
ies (p = 0.42).
ROC curve analysis (see Fig. 3) was performed for all
events where both an ADA and culture for TB were re-
quested on a CSF specimen (n = 1490) and an AUC of
0.86 (95% CI of 0.82 – 0.89, p < 0.01) was obtained. This
analysis together with the Youden index indicates that
the optimal cut-off of CSF ADA in suspected TBM pa-
tients is 2.0 U/L with a sensitivity of 85.9% (95% CI of
77.0 – 92.3) and specificity of 77.7% (95% CI of 75.4 –
79.8%). The positive and negative likelihood ratios were
3.85 and 0.18. It is important to note that, even at this
cut-off, 13 of 92 ‘Confirmed TBM’ cases (14.1%) were
missed (see Table 6). Target and actual sensitivities and
specificities at different CSF ADA levels using this ROC
curve are noted in Table 7.
Training and validation cohorts where determined for
the dataset n = 1490. The AUC of the ROC curve gener-
ated for the training cohort was 0.82 (95% CI of 0.76 –
0.88, p < 0.01). For this curve the Youden index deter-
mined the appropriate CSF ADA cut-off to be 2.20 U/L.
When this cut-off was applied to the validation cohort,
the sensitivity, specificity, positive and negative likeli-
hood ratios were 87.5% (95% CI of 74.8 – 95.3%), 77.9%
(95% CI of 74.6 – 80.9%), 3.96 and 0.16 respectively.
In sub-set ROC analyses performed for each of the 8
categories listed in Table 3, CSF ADA cut-offs were low
(<3 U/L). No optimal cut-off could be determined for
paediatric patients and HIV-negative patients with sus-
pected TBM (see Table 8).
All CSF ADA requests (n = 3548) were re-categorised
according to their integrity and are plotted in Fig. 4. The
majority of the specimens were clear and colourless (n =
3003, 84.6%). Of note is the considerable spread of CSF
ADA results for the ‘Ungraded xanthochromia’ category
compared to the ‘Clear and colourless’ category, both in
terms of outliers and 95% distribution of values. When
excluding all specimens that were not clear and
colourless (n = 545, 15.4%), no change was noted in the
ROC curve analysis and the same cut-off of 2.0 U/L
using the Youden index was determined. Furthermore
the overlap in CSF ADA results for the different categor-
ies remained.
According to the uniform case definition, 68.5% (n =
1024) of cases that had both a CSF ADA and a mycobac-
terial culture requested, fell in the ‘Not TBM’ category.
Of these cases, 20.2% (n = 207) had CSF ADA results ≥ 2
U/L and 6.2% (n = 63) had CSF ADA results ≥ 6 U/L (see
Table 9).
Discussion
TBM is a challenging diagnosis especially in view of the
fact that the diagnostic gold standard, culture, generally
performs so poorly. We aimed to assess the performance
of ADA in all clinical scenarios where CSF sampling was
performed and ADA was requested as part of a patient
work-up. To date this study is the largest and most com-
prehensive analysis of ADA performance in CSF
samples.
An unusually low cut-off for CSF ADA of 2.0 U/L was
determined. This contrasts with the first South African
study on the use of CSF ADA that determined a cut-off
of 6.0 U/L to indicate probable TBM [6]. In the current
study, a similarly low cut-off value (<3 U/L) was deter-
mined for all of the categories according to demography,
Table 4 Statistical comparison of ‘Confirmed TBM’ CSF ADA
results with all CSF ADA results for patients where TB culture on
CSF was absent and or negative (in U/L)
TBM (n = 92) Non-TBM (n = 3456)
Median 5.4000 0.6000 p < 0.01
95% CI 4.1000 – 6.6875 0.6000 – 0.6000
Ranges 0.0000 - 108.0000 0.0000 - 182.5000
Key to this table: TBM – refers to ‘Confirmed TBM’ patients; Non-TBM – refers
to patients where TB culture on CSF was either not requested or negative
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HIV-status and CD4 count. The non-parametric distri-
bution of the CSF ADA results assessed may have con-
tributed to this unusual finding. Selection bias and
ascertainment bias may have been introduced in the way
the CSF ADA results were chosen. In addition, CSF
ADA performance in the ‘Confirmed TBM’ category was
compared to a significantly larger set of results in pa-
tients where TB culture of CSF was negative (n = 1398)
and may have skewed the ROC curve analysis. Further-
more, pre-analytical and analytical factors may also have
contributed. Similar results were obtained when arbitrar-
ily splitting the dataset (n = 1490) in a training cohort
and a validation cohort. Overfitting of the model is un-
likely to have occurred.
It is important to also note than when confirmed
TBM ADA results were compared with all ADA results
for patients where TB culture on CSF was either not re-
quested or negative, a statistically significant difference
was determined (Table 3). However, the maximum CSF
ADA value for the ‘Non-TBM’ category indicated in
Table 3 is higher than that for the ‘TBM’ category. In
addition, upon detailed comparison of the individual cat-
egories, there is significant overlap regarding each cate-
gory’s 95% distribution of values, as well as their outliers
(Fig. 2). This suggests that the CSF ADA result is not re-
liable for the presumptive diagnosis of TBM. Elevations
in non-infectious pathologies have also been noted by
other researchers [3, 18].
In clinical practice CSF ADA is used for rule-in pur-
poses. If CSF ADA is used for rule-in/screening purposes
the sensitivity should be optimized, but this may result
in the cut-off of 2.0 U/L being dropped even further in
the current data set. If ADA is used for rule-out pur-
poses the specificity should be optimized, resulting in an
elevation of the cut-off with a considerable loss of sensi-
tivity (see Table 7) in the current data set. Given the


































Ranges 0.0000 – 108.0000 0.2000 – 56.1000 0.2000 – 8.0000 0.3000 – 86.3000 0.6000 – 135.7000
Fig. 3 ROC plot for all patients that had both an ADA and a culture for TB requested on a CSF specimen
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catastrophic nature of untreated TBM, the consequence
of failing to give appropriate therapy in true TBM are
considerably worse than the consequences of inadvert-
ently over-treating the disease. The positive likelihood
ratio was lower than that published in a recent meta-
analysis, whereas the negative likelihood ratio was simi-
lar [19]. A positive likelihood ratio of 3.85 does increase
the chance of a diagnosis of TBM significantly if there is
a high pretest probability of disease. A negative likeli-
hood ratio of 0.18 is of some value if the pretest prob-
ability is low as it makes the diagnosis of TBM more
than 5-fold less likely. Conversely in all other situations
of pretest probabilities, the test is essentially non-
contributory. Although these parameters suggest a rea-
sonable performance of CSF ADA, it is of concern that
at a cut-off of 2.0 U/L, 13 out of 92 cases of TBM were
missed.
When comparing ADA values between prominent in-
fective pathologies (tuberculosis versus other infectious
conditions), the absence of a statistically significant dif-
ference between the ‘Confirmed bacterial meningitis’ and
‘Confirmed TBM’ categories concurred with findings of
a number of studies [18, 20, 21]. Similarly there was no
statistically significant difference between the ‘Confirmed
ventriculitis’ category and the ‘Confirmed TBM’ category.
CSF ADA results were statistically significantly different
between the ‘Viral meningitis/encephalitis’ and ‘Con-
firmed TBM’ categories. This concurred with the re-
search by Donald, et al. [18]. Coovadia, et al. did not
find any difference between the 2 categories [21]. A sta-
tistically significant difference was found when compar-
ing CSF ADA results between the ‘Confirmed
cryptococcal meningitis’ and ‘Confirmed TBM’ categor-
ies. Rohani, et al. determined a mean CSF ADA result
for TBM cases and those with cryptococcal meningitis
as 16.33+/−5.66 U/L and 7.26+/−3.80 U/L respectively.
Three of the CSF ADA values for cryptococcal meningi-
tis overlapped with the TBM category in this study [22].
In a country like South Africa, where the HIV seropreva-
lence is high and both TB and cryptococcal infections
are important opportunistic co-morbidities, this
phenomenon warrants further investigation.
In the 3548 CSF ADA requests reviewed, results for
the categories according to demography, HIV status and
CD4 cell count yielded a statistically significant differ-
ence for all. Statistically significant differences in ADA
results in adult and paediatric patients are in keeping
with the work by Donald and colleagues [23]. It has been
postulated that a difference in immunological reactivity
to tubercular antigen between adult and paediatric pa-
tients account for this difference [1]. The reason for the
difference in CSF ADA performance between male and
female patients is not clear from the literature. It was
unexpected to find ADA results to be higher in HIV
positive patients and patients with CD4 cell counts less
than or equal to 350 × 106/L as intuitively it is assumed
that cellular responses are impaired in these patients.
Co-morbidities may account for this. Information on
treatment for HIV was not collected. It is assumed that
if cases were on treatment immune reconstitution would
be seen, hence elevated values. Although these




True positive (n) 79
True negative (n) 1086
False positive (n) 312
False negative (n) 13
Sensitivity (%) 85.9
95% confidence interval 77.0–92.3
Specificity (%) 77.7
95% confidence interval 75.4–79.8
Positive likelihood ratio 3.85
Negative likelihood ratio 0.18
Table 7 Target and actual sensitivities and specificities at different CSF ADA levels
Target Sensitivity First cut-off closest the these targets Actual Sensitivity Corresponding Specificity
≥80% 2.3 U/L 81.5% 79.4%
≥85% 2.0 U/L 85.9% 77.7%
≥90% 0.8 U/L 91.3% 57.4%
≥95% 0.5 U/L 95.7% 43%
Target Specificity First cut-off closest the these targets Actual Specificity Corresponding Sensitivity
≥80% 2.4 U/L 80% 78.3%
≥85% 3.3 U/L 85% 68.5%
≥90% 4.5 U/L 90% 55.4%
≥95% 7.3 U/L 95% 33.7%
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differences were statistically significant (p < 0.05), in all
cases the median CSF ADA values were less than 1.0 U/
L.
Several pre-analytical and analytical factors limit ad-
equate interpretation of the results from this study. No
specific specimen collection and handling procedures
are noted in the Diazyme kit package insert (Diazyme,
United States of America) regarding CSF samples. There
are no guidelines regarding the stability of ADA specific-
ally in CSF samples. It is unclear what the correct speci-
men volume should be for optimal assay performance.
Feres and colleagues mention in their validation of the
Diazyme assay for measurement of ADA (Diazyme,
United States of America) in CSF that 22 μL was used
[24]. This is different from the 5 μL mentioned in the
Diazyme kit package insert (Diazyme, United States of
America).
It is important to note the effect of sample integrity on
ADA. ‘Ungraded xanthochromia’ accounted for 81 speci-
mens and showed the widest distribution of 95% of their
values. Both this category and samples assigned xantho-
chromia +/− to 2+ (accounting for 52 or 1.5% of










(%)AUC p value Cut-off (U/L)
Adult patients 90 1345 0.86 <0.01 2.0/2.2 86.7/85.6 77.8/79.0
Paediatric patients 2 53 0.58 <0.33 0.6 100.0 41.5
Male patients 47 695 0.86 <0.01 2.2 (2.0) 89.4 (89.4) 75.3 (74.1)
Female patients 45 703 0.86 <0.01 2.0 82.2 81.1
HIV positive patients 77 846 0.83 <0.01 2.2 (2.0) 84.4 (85.7) 74.1 (72.8)
HIV negative patients 7 274 0.88 <0.01 0.6 100.0 70.1
Patients with CD4 count≤ 350 × 106/L 58 653 0.83 <0.01 2.0 86.2 74.4
Patients with CD4 count < 350 × 106/L 4 114 0.93 <0.01 2.7 100.0 86.0
Cut-offs represented was based on the Youden index. In adult patients the Youden index performed similar for cut-off of 2.0 U/L and 2.2 U/L. In brackets
performance at a cut-off of 2.0 U/L is indicated
Fig. 4 CSF ADA values plotted according to the specimen integrity comments for each sample. The 95% distribution of values (including the median, first
and third IQRs) and the outliers are indicated. Key to this Figure: 1 – ungraded bloodstained (n = 13), 2 – bloodstained +/− to 2+ (n = 196), 3 –
bloodstained 3+ to 4+ (n = 28), 4 – ungraded xanthochromia (n = 81), 5 – xanthochromia +/− to 2+ (n = 52), 6 – xanthochromia 3+ to 4+ (n = 6), 7 –
ungraded turbid (n = 11), 8 – turbid +/− to 2+ (n = 148), 9 – turbid 3+ to 4+ (n = 10), 10 – clear and colourless (n = 3003); CI - confidence interval;
IQR – interquartile range
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samples) showed a wide scatter in their outliers, similar
to the category for clear and colourless samples (ac-
counting for 3003 or 84.6% of samples). Ungerer and
colleagues demonstrated that erythrocytes contribute
100% of ADA-1 (ADA isoform 1) and polymorpho-
nuclear cells contribute 70% ADA-1 and 30% ADA-1 +
CP (two ADA isoform 1 molecules connected by a com-
bining protein) to the total ADA activity in cell extracts
[25]. This may explain the performance of CSF ADA in
the ‘Confirmed Ventriculitis’ category.
Using a uniform case definition for TBM [17], by
weighting the available evidence collected, about two-
thirds of cases (n = 1024, 68.7%) whom had a CSF ADA
and mycobacterial culture requested, fell in the ‘Not
TBM’ category. By applying the CSF ADA cut-off of 2.0
U/L, about a fifth of these cases (n = 207, 20.2%) would
have been treated if the decision to treat was based on
the CSF ADA alone. This is about three times more than
the number of patients that would have been treated
using a cut-off of 6.0 U/L (n = 63, 6.2%). Either way, irre-
spective of whether a cut-off of 2.0U/L or 6.0 U/L is
used, a considerable number of patients would have re-
ceived unnecessary treatment. The uniform case defin-
ition was established after extensive literature review
and international expert consensus [17]. Although the
current study is subject to limitations, the performance
of CSF ADA is such that it simply cannot supersede the
uniform case definition (see Table 9).
The measurement of ADA in general is complicated by
poor standardisation [26]. Giusti and non-Giusti methods
have been documented. Most methods are in-house based.
The Diazyme assay (Diazyme, United States of America) is
a commercially available assay fit for automated platforms.
Bota and colleagues produced and certified enzyme refer-
ence material for ADA-1 to be used to compare laborator-
ies and verify performance of calibration material and
quality control material. This group utilised ADA purified
from human erythrocytes. A commutability study was only
performed on pleural fluid samples clear of haemolysis and
turbidity [27]. The poor standardisation of ADA measure-
ment makes it difficult to interpret the significance of CSF
ADA values in the literature. Both the calibrator and con-
trol material supplied by Diazyme (Diazyme, United States
of America) are bovine serum albumin based. An import-
ant question to resolve is how matrix effects interfere with
this assay.
No consensus exists regarding the linear range of this
assay. The calibration curve for the Diazyme assay
(Diazyme, United States of America) lies between 0 – 50
U/L. However, the package insert for the Diazyme assay
(Diazyme, United States of America) states that dilution
should occur for samples with results > 200 U/L. Delacour,
et al., (2010) performed a linearity study and determined
the analytical measurement range to be 0.5 – 120 U/L [28].
Ideally control material should reflect analyte levels at
which clinical decisions are made. Currently this is true for
pericardial, peritoneal and pleural fluids, but not for CSF.
The imprecision of the Diazyme assay (Diazyme, United
States of America) at the proposed cut-off of 2.0 U/L is
unknown. Data from our validation studies at the lower
control level of 10.6 U/L showed a within-run standard
deviation of 0.172 U/L, total standard deviation of 0.601
U/L, and the total coefficient of variation of 5.8%. As the
allowable coefficient of variation was 7.0%, this perform-
ance was deemed to be acceptable. It is possible that the
imprecision of the assay is poor at a cut-off of 2.0 U/L.
This would require further investigation.
The retrospective analysis of clinical and laboratory data
constituted a further limitation of this study. While every
effort was made to find all data parameters relevant to the
study, this was not always possible due to incomplete data
in patient files and on the laboratory information system.
This may have affected the categorisation process. Reflex
testing of CSF ADA may have occurred. Many of the con-
trols will have had a high pretest clinical probability of
other diagnoses. In view of the fact that submission of in-
sufficient CSF volume impacts on the sensitivity of TB
culture, it is possible that microbiological confirmation of
TBM was missed in some cases, as less than 10% of the
1490 patients who had a culture and ADA requested on a
CSF specimen had more than one specimen submitted.
As the majority of the population studied were HIV













Percentage (%) 68.7 20.5 4.6 6.2
ADA Range 0.0 – 135.7 0.0 – 91.8 0.0 – 6.5 0.0 - 108
Median ADA 0.6 0.9 0.7 5.4
Number of cases in
each category ADA≥ 2
n = 207, 20.2% n = 97, 31.7% n = 15, 22.1%
Number of cases in
each category ADA≥ 6
n = 63, 6.2% n = 32, 10.5% n = 4, 5.9%
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positive and for a quarter the HIV status was not known,
these results cannot be extrapolated to non-HIV popula-
tions. This requires further investigation.
Conclusion
The authors cannot recommend CSF ADA as either a
rule-in or a rule-out test. A clinical appropriate cut-off
could not be determined, as at a cut-off of 2.0 U/L still 13
out of 92 cases of ‘Confirmed TBM’ were missed. Several
pre-analytic and analytical factors affect interpretation of
CSF ADA results. No definite conclusions can be reached
regarding CSF ADA cut-off levels, without fully under-
standing these factors. The effect of sample integrity can-
not be underestimated and there is a pressing need for
standardisation of CSF ADA measurement. CSF culture
remains the gold standard for the diagnosis of TBM. Its
poor performance overall, however, makes it a problematic
gold standard to which CSF ADA is compared to and a re-
placement is needed. The data from this study show that
the CSF ADA result may potentially mislead clinicians in
the diagnostic process. As such careful assessment and
weighting of all the available evidence should prove more
fruitful [17]. A future prospective multicentre study on a
larger cohort, especially once the standardisation of CSF
ADA measurement has improved, is advocated. In the
meantime clinicians should be aware of the limitations of
basing a diagnosis of TBM on a CSF ADA result.
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